Chronic stable angina treatment nitrates: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(New page: __NOTOC__ {{Chronic stable angina}} '''Editors-In-Chief:''' C. Michael Gibson, M.S., M.D. [mailto:mgibson@perfuse.org] Phone:617-632-7753; {{CZ}}; '''Associate Editors-In-Chief:''' [[J...)
 
No edit summary
Line 1: Line 1:
__NOTOC__
{{Chronic stable angina}}
{{Chronic stable angina}}
'''Editors-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; {{CZ}}; '''Associate Editors-In-Chief:''' [[John Fani Srour, M.D.]]; Jinhui Wu, MD


==Overview==
'''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; '''Associate Editor(s)-In-Chief:''' {{CZ}}; [[John Fani Srour, M.D.]]; Jinhui Wu, M.D.
'''Mechanism of benefit:'''
 
==Mechanisms of benefit==
*[[Nitroglycerin]] and other nitrates are '''endothelium independent vasodilators''' that produce their beneficial effects both by decreasing myocardial oxygen requirements and by improving myocardial perfusion.  
*[[Nitroglycerin]] and other nitrates are '''endothelium independent vasodilators''' that produce their beneficial effects both by decreasing myocardial oxygen requirements and by improving myocardial perfusion.  
:*It has been postulated that nitrates, after entering the vessel wall, are converted to nitric oxide (NO), which stimulates guanylate cyclase to produce cyclic guanosine mono phosphate (cGMP), the substance that is responsible for vasodilation.
:*Nitrates dilate large coronary arteries and collateral vessels, thereby increasing collateral blood flow to the ischemic myocardium and relieve coronary [[vasospasm]]
:*Nitrates also decrease the degree of coronary artery stenosis produced by an eccentric atherosclerotic plaque.
:*Nitrates also decrease myocardial oxygen requirements by decreasing intra cardiac volumes consequent to reduced venous return resulting from peripheral venous dilatation and by reducing arterial pressure. These beneficial effects may be offset partly by a reflex increase in [[heart rate]], which can be prevented by simultaneous [[beta adrenergic blockade]].


'''Indications:'''
*It has been postulated that nitrates, after entering the vessel wall, are converted to nitric oxide (NO), which stimulates guanylate cyclase to produce cyclic guanosine mono phosphate (cGMP), the substance that is responsible for vasodilation.
 
*Nitrates dilate large coronary arteries and collateral vessels, thereby increasing collateral blood flow to the ischemic myocardium and relieve coronary [[vasospasm]]
*Nitrates also decrease the degree of coronary artery stenosis produced by an eccentric atherosclerotic plaque.
 
*Nitrates also decrease myocardial oxygen requirements by decreasing intra cardiac volumes consequent to reduced venous return resulting from peripheral venous dilatation and by reducing arterial pressure. These beneficial effects may be offset partly by a reflex increase in [[heart rate]], which can be prevented by simultaneous [[beta adrenergic blockade]].
 
==Indications==
*Nitrates are effective for the management of various clinical subsets of stable angina pectoris.


Nitrates are effective for the management of various clinical subsets of stable angina pectoris.  
:*In patients with [[exertional angina]], nitrates improve exercise tolerance, the time to the onset of angina, and [[ST segment depression]] during the treadmill exercise test.


*In patients with [[exertional angina]], nitrates improve exercise tolerance, the time to the onset of angina, and [[ST segment depression]] during the treadmill exercise test.
:*In patients with [[Chronic stable angina clinical subset- vasospastic angina|vasospastic angina]], nitrates relax the smooth muscles of the epicardial coronary arteries and thereby relieve coronary artery spasm.  


*In patients with [[Chronic stable angina clinical subset- vasospastic angina|vasospastic angina]], nitrates relax the smooth muscles of the epicardial coronary arteries and thereby relieve coronary artery spasm.  
:*In patients with [[Chronic stable angina clinical subset- mixed angina pectoris|mixed angina]] and [[Chronic stable angina clinical subset- postprandial angina pectoris|postprandial angina]], nitrates reduce myocardial oxygen demand and promote coronary vasodilation.


*In patients with [[Chronic stable angina clinical subset- mixed angina pectoris|mixed angina]] and [[Chronic stable angina clinical subset- postprandial angina pectoris|postprandial angina]], nitrates reduce myocardial oxygen demand and promote coronary vasodilation.
*'''Prophylaxis with Nitrates:'''
:*Nitroglycerin is also very useful for prophylaxis when used several minutes before planned exertion. However, its short duration of action (20 to 30 min) makes it less practical for long-term prevention of ischemia in patients with stable angina.


'''Nitrates Dosing:'''
:*For angina prophylaxis, long acting nitrate preparations such as [[isosorbide dinitrate]], mono nitrates, transdermal nitroglycerin patches, and nitroglycerin paste are preferable.


==Contra-indications==
*Nitrates do not worsen [[glaucoma]], once thought to be a contraindication to their use, and they can be used safely in the presence of increased intraocular pressure.
*Nitrates are relatively contraindicated in [[hypertrophic obstructive cardiomyopathy]], because in these patients, nitrates can increase LV outflow tract obstruction and severity of [[mitral regurgitation]] and can precipitate presyncope or [[syncope]]. For the same reason, nitrates should be avoided in patients with [[aortic valve stenosis]].
==Dosage==
A variety of nitrate preparations are currently available.  
A variety of nitrate preparations are currently available.  


Line 29: Line 38:
*[[Isosorbide dinitrate]] should not be used more frequently than three times a day, or a transdermal patch more often than every 12 hours.
*[[Isosorbide dinitrate]] should not be used more frequently than three times a day, or a transdermal patch more often than every 12 hours.


'''Prophylaxis with Nitrates:'''
==Adverse effects==
*Nitroglycerin is also very useful for prophylaxis when used several minutes before planned exertion. However, its short duration of action (20 to 30 min) makes it less practical for long-term prevention of ischemia in patients with stable angina.
*Throbbing headache, which tends to decrease with continued use.  
 
*Postural dizziness and weakness occur in some patients, frank syncope due to hypotension is relatively uncommon.  
*For angina prophylaxis, long acting nitrate preparations such as [[isosorbide dinitrate]], mono nitrates, transdermal nitroglycerin patches, and nitroglycerin paste are preferable.  


'''Nitrate Tolerance:'''
'''Nitrate Tolerance:'''
Line 45: Line 53:
*However, the most reliable method for the prevention of nitrate tolerance is to ensure a '''nitrate free period of approximately 10 hours''', usually including sleeping hours, in patients with effort angina.  
*However, the most reliable method for the prevention of nitrate tolerance is to ensure a '''nitrate free period of approximately 10 hours''', usually including sleeping hours, in patients with effort angina.  


'''Side Effects:'''
==ACC/AHA Guidelines- Pharmacotherapy to Prevent MI and Death and Reduce Symptoms (DO NOT EDIT) <ref name="pmid10351980">Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999)[http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10351980ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).]''Circulation'' 99 (21):2829-48. PMID: [http://pubmed.gov/10351980 10351980]</ref><ref name="pmid12515758">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12515758 ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).] ''Circulation'' 107 (1):149-58. PMID: [http://pubmed.gov/12515758 12515758]</ref>==
*Throbbing headache, which tends to decrease with continued use.
*Postural dizziness and weakness occur in some patients, frank syncope due to hypotension is relatively uncommon.
 
'''Contraindications:'''
*Nitrates do not worsen [[glaucoma]], once thought to be a contraindication to their use, and they can be used safely in the presence of increased intraocular pressure.
*Nitrates are relatively contraindicated in [[hypertrophic obstructive cardiomyopathy]], because in these patients, nitrates can increase LV outflow tract obstruction and severity of [[mitral regurgitation]] and can precipitate presyncope or [[syncope]]. For the same reason, nitrates should be avoided in patients with [[aortic valve stenosis]].
 
==ACC/AHA Guidelines- Pharmacotherapy to Prevent MI and Death and Reduce Symptoms (DO NOT EDIT)<ref name="pmid10351980">Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999)[http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10351980ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).]''Circulation'' 99 (21):2829-48. PMID: [http://pubmed.gov/10351980 10351980]</ref><ref name="pmid12515758">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12515758 ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).] ''Circulation'' 107 (1):149-58. PMID: [http://pubmed.gov/12515758 12515758]</ref>==
{{cquote|
{{cquote|
===Class I===
===Class I===
'''1.''' [[Calcium channel blocker]] (short-acting [[dihydropyridine calcium antagonist]]s should be avoided) and/or long-acting nitrates as initial therapy when [[beta blockers]] are contraindicated. ''(Level of Evidence: B)''
'''1.''' [[Chronic stable angina calcium channel blocker therapy|Calcium channel blocker]] (short-acting [[dihydropyridine calcium antagonist]]s should be avoided) and/or long-acting nitrates as initial therapy when [[Chronic stable angina beta blocker therapy|beta blockers]] are contraindicated. ''(Level of Evidence: B)''


'''2.''' [[Calcium channel blocker]] (short-acting [[dihydropyridine calcium antagonist]]s should be avoided) and/or long-acting nitrates in combination with [[beta blockers]] when initial treatment with [[beta blockers]] is not successful. ''(Level of Evidence: B)''
'''2.''' [[Chronic stable angina calcium channel blocker therapy|Calcium channel blocker]] (short-acting [[dihydropyridine calcium antagonist]]s should be avoided) and/or long-acting nitrates in combination with [[Chronic stable angina beta blocker therapy|beta blockers]] when initial treatment with [[Chronic stable angina beta blocker therapy|beta blockers]] is not successful. ''(Level of Evidence: B)''


'''3.''' [[Calcium channel blocker]] (short-acting [[dihydropyridine calcium antagonist]]s should be avoided) and/or long-acting nitrates as a substitute for [[beta blockers]] if initial treatment with [[beta blockers]] leads to unacceptable side effects. ''(Level of Evidence: C)''
'''3.''' [[Chronic stable angina calcium channel blocker therapy|Calcium channel blocker]] (short-acting [[dihydropyridine calcium antagonist]]s should be avoided) and/or long-acting nitrates as a substitute for [[Chronic stable angina beta blocker therapy|beta blockers]] if initial treatment with [[Chronic stable angina beta blocker therapy|beta blockers]] leads to unacceptable side effects. ''(Level of Evidence: C)''


'''4.''' Sublingual [[nitroglycerin]] or nitroglycerin spray for the immediate relief of [[angina]]. ''(Level of Evidence: C)''}}
'''4.''' Sublingual [[nitroglycerin]] or nitroglycerin spray for the immediate relief of [[angina]]. ''(Level of Evidence: C)''}}


==See Also==
==ESC Guidelines- Pharmacological therapy to improve symptoms and/or reduce ischaemia in patients with stable angina (DO NOT EDIT)<ref name="pmid16735367">{{cite journal| author=Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F et al.| title=Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. | journal=Eur Heart J | year= 2006 | volume= 27 | issue= 11 | pages= 1341-81 | pmid=16735367 | doi=10.1093/eurheartj/ehl001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735367}}</ref>==
*[[The Living Guidelines: Chronic Stable Angina Pectoris | The Chronic Stable Angina Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]]
{{cquote|
===Class I===
'''1.''' Provide short-acting nitroglycerin for acute symptom
relief and situational prophylaxis, with appropriate
instructions on how to use the treatment. ''(Level of Evidence: B)''


==Sources==
'''2.''' In case of [[Chronic stable angina beta blocker therapy|beta-blocker]] intolerance or poor efficacy attempt monotherapy with a [[Chronic stable angina calcium channel blocker therapy|CCB]] ''(Level of Evidence: A)'', long-acting nitrate ''(Level of Evidence: C)'', or [[nicorandil]] ''(Level of Evidence: C)''.
*The ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina <ref name="pmid10351980">Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10351980 ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).] ''Circulation'' 99 (21):2829-48. PMID: [http://pubmed.gov/10351980 10351980]</ref>


*TheACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina <ref name="pmid12515758">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12515758 ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).] ''Circulation'' 107 (1):149-58. PMID: [http://pubmed.gov/12515758 12515758]</ref>
===Class IIa===
'''1.''' If [[Chronic stable angina calcium channel blocker therapy|CCB]] monotherapy or combination therapy ([[Chronic stable angina calcium channel blocker therapy|CCB]] with [[Chronic stable angina beta blocker therapy|beta-blocker]]) is unsuccessful, substitute the [[Chronic stable angina calcium channel blocker therapy|CCB]] with a
long-acting nitrate or [[nicorandil]]. Be careful to avoid nitrate tolerance. ''(Level of Evidence: C)''}}


*The 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina <ref name="pmid17998462">Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17998462 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina.] ''Circulation'' 116 (23):2762-72. [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.187930 DOI:10.1161/CIRCULATIONAHA.107.187930] PMID: [http://pubmed.gov/17998462 17998462]</ref>
==Vote on and Suggest Revisions to the Current Guidelines==
*[[The Living Guidelines: Chronic Stable Angina Pectoris | The Chronic Stable Angina Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]]
==Sources==
*Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology <ref name="pmid16735367">{{cite journal| author=Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F et al.| title=Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. | journal=Eur Heart J | year= 2006 | volume= 27 | issue= 11 | pages= 1341-81 | pmid=16735367 | doi=10.1093/eurheartj/ehl001 | pmc= |url=url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735367 [http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-angina-FT.pdf]}} </ref>
*The ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina <ref name="pmid10351980">Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10351980 ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).] ''Circulation'' 99 (21):2829-48. [http://circ.ahajournals.org/content/99/21/2829.full.pdf] PMID: [http://pubmed.gov/10351980 10351980]</ref>
*TheACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina <ref name="pmid12515758">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12515758 ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).] ''Circulation'' 107 (1):149-58.[http://content.onlinejacc.org/cgi/reprint/41/1/159.pdf] PMID: [http://pubmed.gov/12515758 12515758]</ref>
*The 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina <ref name="pmid17998462">Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007)[http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17998462 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina.] ''Circulation'' 116 (23):2762-72.[http://content.onlinejacc.org/cgi/reprint/50/23/2264.pdf] PMID: [http://pubmed.gov/17998462 17998462]</ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category: Disease state]]  
[[Category:Ischemic heart diseases]]
[[Category: Ischemic heart diseases]]
[[Category:Disease state]]
[[Category: Cardiology]]
[[Category:Cardiology]]
[[Category: Emergency medicine]]
[[Category:Emergency medicine]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 14:45, 19 August 2011

Chronic stable angina Microchapters

Acute Coronary Syndrome Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Classic
Chronic Stable Angina
Atypical
Walk through Angina
Mixed Angina
Nocturnal Angina
Postprandial Angina
Cardiac Syndrome X
Vasospastic Angina

Differentiating Chronic Stable Angina from Acute Coronary Syndromes

Pathophysiology

Epidemiology and Demographics

Risk Stratification

Pretest Probability of CAD in a Patient with Angina

Prognosis

Diagnosis

History and Symptoms

Physical Examination

Test Selection Guideline for the Individual Basis

Laboratory Findings

Electrocardiogram

Exercise ECG

Chest X Ray

Myocardial Perfusion Scintigraphy with Pharmacologic Stress

Myocardial Perfusion Scintigraphy with Thallium

Echocardiography

Exercise Echocardiography

Computed coronary tomography angiography(CCTA)

Positron Emission Tomography

Ambulatory ST Segment Monitoring

Electron Beam Tomography

Cardiac Magnetic Resonance Imaging

Coronary Angiography

Treatment

Medical Therapy

Revascularization

PCI
CABG
Hybrid Coronary Revascularization

Alternative Therapies for Refractory Angina

Transmyocardial Revascularization (TMR)
Spinal Cord Stimulation (SCS)
Enhanced External Counter Pulsation (EECP)
ACC/AHA Guidelines for Alternative Therapies in patients with Refractory Angina

Discharge Care

Patient Follow-Up
Rehabilitation

Secondary Prevention

Guidelines for Asymptomatic Patients

Noninvasive Testing in Asymptomatic Patients
Risk Stratification by Coronary Angiography
Pharmacotherapy to Prevent MI and Death in Asymptomatic Patients

Landmark Trials

Case Studies

Case #1

Chronic stable angina treatment nitrates On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic stable angina treatment nitrates

CDC onChronic stable angina treatment nitrates

Chronic stable angina treatment nitrates in the news

Blogs on Chronic stable angina treatment nitrates

to Hospitals Treating Chronic stable angina treatment nitrates

Risk calculators and risk factors for Chronic stable angina treatment nitrates

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Phone:617-632-7753; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [3]; John Fani Srour, M.D.; Jinhui Wu, M.D.

Mechanisms of benefit

  • Nitroglycerin and other nitrates are endothelium independent vasodilators that produce their beneficial effects both by decreasing myocardial oxygen requirements and by improving myocardial perfusion.
  • It has been postulated that nitrates, after entering the vessel wall, are converted to nitric oxide (NO), which stimulates guanylate cyclase to produce cyclic guanosine mono phosphate (cGMP), the substance that is responsible for vasodilation.
  • Nitrates dilate large coronary arteries and collateral vessels, thereby increasing collateral blood flow to the ischemic myocardium and relieve coronary vasospasm
  • Nitrates also decrease the degree of coronary artery stenosis produced by an eccentric atherosclerotic plaque.
  • Nitrates also decrease myocardial oxygen requirements by decreasing intra cardiac volumes consequent to reduced venous return resulting from peripheral venous dilatation and by reducing arterial pressure. These beneficial effects may be offset partly by a reflex increase in heart rate, which can be prevented by simultaneous beta adrenergic blockade.

Indications

  • Nitrates are effective for the management of various clinical subsets of stable angina pectoris.
  • In patients with vasospastic angina, nitrates relax the smooth muscles of the epicardial coronary arteries and thereby relieve coronary artery spasm.
  • Prophylaxis with Nitrates:
  • Nitroglycerin is also very useful for prophylaxis when used several minutes before planned exertion. However, its short duration of action (20 to 30 min) makes it less practical for long-term prevention of ischemia in patients with stable angina.
  • For angina prophylaxis, long acting nitrate preparations such as isosorbide dinitrate, mono nitrates, transdermal nitroglycerin patches, and nitroglycerin paste are preferable.

Contra-indications

  • Nitrates do not worsen glaucoma, once thought to be a contraindication to their use, and they can be used safely in the presence of increased intraocular pressure.
  • Nitrates are relatively contraindicated in hypertrophic obstructive cardiomyopathy, because in these patients, nitrates can increase LV outflow tract obstruction and severity of mitral regurgitation and can precipitate presyncope or syncope. For the same reason, nitrates should be avoided in patients with aortic valve stenosis.

Dosage

A variety of nitrate preparations are currently available.

  • The onset of action of sublingual nitroglycerin tablets or nitroglycerin spray is within 1 to 3 minutes, making these the preferred agents for the acute relief of effort or rest angina.
  • The patient should be instructed that active nitroglycerin will cause some tingling under the tongue, and that if this does not occur, the efficacy of their nitroglycerine tablets may be expired.
  • Isosorbide dinitrate should not be used more frequently than three times a day, or a transdermal patch more often than every 12 hours.

Adverse effects

  • Throbbing headache, which tends to decrease with continued use.
  • Postural dizziness and weakness occur in some patients, frank syncope due to hypotension is relatively uncommon.

Nitrate Tolerance:

  • Tolerance develops not only to antianginal and hemodynamic effects but also to platelet antiaggregatory effects.
  • The mechanism for development of nitrate tolerance remains unclear.
  • The decreased availability of sulfhydryl (SH) radicals, activation of the renin-angiotensin-aldosterone system, an increase in intravascular volume due to an altered transvascular Starling gradient, and generation of free radicals with enhanced degradation of nitric oxide have been proposed.
  • The concurrent administration of an SH donor such as SH-containing ACE inhibitors, acetyl or methyl cysteine ,and diuretics has been suggested to reduce the development of nitrate tolerance.
  • Concomitant administration of hydralazine has also been reported to reduce nitrate tolerance.
  • However, the most reliable method for the prevention of nitrate tolerance is to ensure a nitrate free period of approximately 10 hours, usually including sleeping hours, in patients with effort angina.

ACC/AHA Guidelines- Pharmacotherapy to Prevent MI and Death and Reduce Symptoms (DO NOT EDIT) [1][2]

“

Class I

1. Calcium channel blocker (short-acting dihydropyridine calcium antagonists should be avoided) and/or long-acting nitrates as initial therapy when beta blockers are contraindicated. (Level of Evidence: B)

2. Calcium channel blocker (short-acting dihydropyridine calcium antagonists should be avoided) and/or long-acting nitrates in combination with beta blockers when initial treatment with beta blockers is not successful. (Level of Evidence: B)

3. Calcium channel blocker (short-acting dihydropyridine calcium antagonists should be avoided) and/or long-acting nitrates as a substitute for beta blockers if initial treatment with beta blockers leads to unacceptable side effects. (Level of Evidence: C)

4. Sublingual nitroglycerin or nitroglycerin spray for the immediate relief of angina. (Level of Evidence: C)

”

ESC Guidelines- Pharmacological therapy to improve symptoms and/or reduce ischaemia in patients with stable angina (DO NOT EDIT)[3]

“

Class I

1. Provide short-acting nitroglycerin for acute symptom relief and situational prophylaxis, with appropriate instructions on how to use the treatment. (Level of Evidence: B)

2. In case of beta-blocker intolerance or poor efficacy attempt monotherapy with a CCB (Level of Evidence: A), long-acting nitrate (Level of Evidence: C), or nicorandil (Level of Evidence: C).

Class IIa

1. If CCB monotherapy or combination therapy (CCB with beta-blocker) is unsuccessful, substitute the CCB with a long-acting nitrate or nicorandil. Be careful to avoid nitrate tolerance. (Level of Evidence: C)

”

Vote on and Suggest Revisions to the Current Guidelines

Sources

  • Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology [3]
  • The ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina [1]
  • TheACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina [2]
  • The 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina [4]

References

  1. ↑ 1.0 1.1 Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999)guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).Circulation 99 (21):2829-48. PMID: 10351980
  2. ↑ 2.0 2.1 Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 107 (1):149-58. PMID: 12515758
  3. ↑ 3.0 3.1 Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F; et al. (2006). "Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology". Eur Heart J. 27 (11): 1341–81. doi:10.1093/eurheartj/ehl001. PMID 16735367.
  4. ↑ Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007)2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 116 (23):2762-72.[1] PMID: 17998462


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_stable_angina_treatment_nitrates&oldid=592779"